Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.

By J. Pépin, M. Alary, Louis Valiquette, É. Raiche, J. Ruel, Katalin Fulop, D. Godin, C. Bourassa. Clinical Infectious Diseases, 2005

608 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/907b9409ff065a41b926bcdf26f648a70c3f7d53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. Victoria J. Fraser

In Infectious Diseases

1. Louis Valiquette
2. Benoît Cossette
3. J. Pépin
4. J. H. Morse

Citations in the corpus

• A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. (2007, background): “more-severe disease [4, 8, 10, 29], an increased number of relapses after metronidazole therapy [8, 30], and occurrence of”
• European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. (2014, background): “[117] Metronidazole 632 98 6 92 Vancomycin 122 99 10 89 [57] Metronidazole 44 ? 50 – [118] Metronidazole 99 62 ? – [119] Metronidazole 207 78 28 56 [68] Metronidazole 1123 84 29 60 Vancomycin 112 ? 28 [120] Fidaxomicin varying dose 45 91 5 86”
• Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec (2005, methodology): “A database comprising all cases of CDAD diagnosed at CHUS since 1991 is regularly updated by review of laboratory reports and discharge diagnoses and by periodic searches of the hospital’s computerized medical records.(4,11) The CHUS laboratory is the only one in the region performing the C.”
• Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). (2018, unknown): “The recent randomized trial data (Table 6) [170, 188] have confirmed prior observational studies that demonstrated decreased effectiveness of oral metronidazole [312, 313].”
• Factors affecting the composition of the gut microbiota, and its modulation (2019, background): “Probiotics rarely remain in the colon more than 14 days after the patient ceases taking them, while the effects of FMTon the gut microbiota can persist for 24 weeks (Pepin et al., 2005; Kelly & LaMont, 2008), indicating that FMT can cause pronounced changes in the gut microbiota (Mattila et al.”
• Development and Validation of a Clostridium difficile Infection Risk Prediction Model (2011, background): “Bone Marrow Transplant 2000;26(8):871–876.”